United States
You have no items in your shopping cart.
Publications citing Adooq Products
Obatoclax mesylate (GX15-070) Citations (2)
- Chi-Hung R. Or,et al. Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells, Int J Mol Sci, 2016, Jan; 18(1): 44 28035994
- P Geserick,et al. The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin, Cell Death Dis., 2014, 5(9): e1412 25210795
Chemical Information
| Catalog Num | A10665 |
|---|---|
| Actions | Inhibitor |
| M. Wt | 413.5 |
| Formula | C20H19N3O.CH4O3S |
| Solubility | DMSO>83mg/mL Water<1mg/mL Ethanol<1mg/mL |
| Purity | >98% |
| Storage | at -20°C 3 years Powder |
| CAS No. | 803712-79-0 |
| Synonyms | N/A |
| SMILES code | CC1=CC(=C(N1)/C=C/2\C(=C/C(=C\3/C=C4C=CC=CC4=N3)/N2)OC)C.CS(=O)(=O)O |
| Chemical Name | 2-[2-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylene]-3-methoxy-2H-pyrrol-5-yl]-1H-indole methanesulfonate |
Description |
Bcl-2 homology domain-3 (BH3) mimetic,antagonize all antiapoptotic Bcl-2 family proteins (average IC50, 3 umol/L), including Mcl-1 (IC50, 2.9 umol/L) and Bfl-1 (IC50, 5 umol/L). | ||||||||||
Targets |
|
||||||||||
| Solubility (25°C) * | In vitro | DMSO | 83 mg/mL (200.73 mM) |
|---|---|---|---|
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | <1 mg/mL (<1 mM) | ||
| In vivo | 30% PEG400/0.5% Tween80/5% propylene glycol | 30 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 24.18 mL | 120.92 mL | 241.84mL |
| 0.5 mM | 4.84 mL | 24.18 mL | 48.37 mL |
| 1 mM | 2.42 mL | 12.09 mL | 24.18 mL |
| 5 mM | 0.48 mL | 2.42 mL | 4.84 mL |
*The above data is based on the productmolecular weight 413.5. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Biological Activity
| Description | Obatoclax (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 1/2. | |||||
|---|---|---|---|---|---|---|
| Targets | Bcl-2 | |||||
| IC50 | 0.22 μM (Ki) [1] | |||||
| In vitro | Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3] | |||||
| In vivo | Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1] | |||||
| Features | Obatoclax is a potential first-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant members of the Bcl-2 family of proteins, including the dominant member, Mcl-1. | |||||
Protocol(Only for Reference)
Kinase Assay: [1]
| Bcl-2 Binding affinity calculation | A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2. |
|---|
Cell Assay: [2]
| Cell lines | Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) |
|---|---|
| Concentrations | ~10 μM |
| Incubation Time | 48-72 hours |
| Method | Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined. |
Animal Study: [1]
| Animal Models | Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used. |
|---|---|
| Formulation | Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 mg/mL mannitol, and 5% dextrose. |
| Dosages | 0.0313, 0.25, 0.5 and 2 mg/kg |
| Administration | Administered intravenously (tail vein) once a day |
Reference
1. Nguyen M, et al. Proc Natl Acad Sci, 2007, 104(49), 19512-191517.
2. Trudel S, et al. Blood, 2009, 113(2), 299-305.
3. Huang S, et al. Clin Cancer Res, 2009, 15 (1), 150-159.
4. Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.
Clinical Trial Information( data from http://clinicaltrials.gov)
| NCT Number | Recruitment | Conditions | Sponsor /Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00918931 | Terminated | Leukemia|Systemic Mastocytosis | M.D. Anderson Cancer Center|Gemin X | 2009-06 | Phase 2 |
| NCT00933985 | Active, not recruiting | Acute Undifferentiated Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma etc. | National Cancer Institute (NCI) | 2009-06 | Phase 1 |
| NCT01150656 | Active, not recruiting | Leukemia | National Cancer Institute (NCI)|Children's Oncology Group | 2010-06 | |
| NCT01238146 | Withdrawn | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma etc. | National Cancer Institute (NCI) | 2010-10 | Phase 1|Phase 2 |
| NCT01563601 | Withdrawn | Extensive-stage Small Cell Lung Cancer | Teva Pharmaceutical Industries|Cephalon | 2012-08 | Phase 3 |
|
Cat. No. | Product Name | Solubility(mg/mL) | ||
|---|---|---|---|---|
| Water | DMSO | Ethanol | ||
| A10255 | ABT-737 | <1 mg/mL | 163 mg/mL | <1 mg/mL |
| A10022 | ABT-263 (Navitoclax) | <1 mg/mL | 195 mg/mL | <1 mg/mL |
| A10665 | Obatoclax mesylate (GX15-070) | <1 mg/mL | 83 mg/mL | <1 mg/mL |
| A10955 | TW-37 | <1 mg/mL | 115 mg/mL | 4 mg/mL |
| A10984 | VX-765 | <1 mg/mL | 102 mg/mL | 102 mg/mL |
| A11090 | PAC-1 | <1 mg/mL | 78 mg/mL | 16 mg/mL |
| A10491 | JNJ 26854165 | <1 mg/mL | 66 mg/mL | 2 mg/mL |
| A11931 | RITA (NSC 652287) | <1 mg/mL | 115 mg/mL | 4 mg/mL |
| A10522 | Lenalidomide (CC-5013) | <1 mg/mL | 52 mg/mL | <1 mg/mL |
| A10743 | Pomalidomide (CC-4047) | <1 mg/mL | 55 mg/mL | <1 mg/mL |
| A11163 | AT-406 | <1 mg/mL | 112 mg/mL | 112 mg/mL |
| A11002 | YM155 | 89 mg/mL | 55 mg/mL | 6 mg/mL |
| A10935 | Tipifarnib (Zarnestra) | <1 mg/mL | 83 mg/mL | <1 mg/mL |
| A10657 | Nutlin-3 | <1 mg/mL | 116 mg/mL | 116 mg/mL |
Ordering online
To place an order online, simply browse to the product you are interested in and click on the 'Add to Cart' button. To complete this process, you will need to confirm the size and quantity of the products that you require.
To complete an order you will need to register using our simple online registration process. We do not share your contact details with any third parties.
When you are ready to check out simply enter your PO number to complete the ordering process. Please ensure that you send us a copy of your PO by fax or email afterwards. We will then liaise with you or your purchasing department to confirm the order.
Found your products but not ready to order?
Why not use our WishList feature to store lists of products? This convenient feature allows you to manage lists, append notes to products and share lists with co-workers or colleagues.
Ordering offline
You can email or fax us your purchase order and we will place the order for you. You can also phone us to place the order. Our contact details are:
- Tel: 866-930-6790
- Fax: 323-606-8156
- Email: [email protected]
We require the following information to process your order:
- The catalog number for each product.
- Your email address or fax number.
- Your name and telephone number.
- Shipping address and billing address.
- Purchase order numbers.
Similar product(s)
Special Price Starting at:
$45.00
ABT-737 is a pan-Bcl-2 inhibitor. IC50 values ranged from 192 nM (the pre-B cell line Hal-01) to <10 μM (Nalm-6, K562 and HL-60). ...
Special Price Starting at: $45.00
Special Price Starting at:
$90.00
UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
...
Special Price Starting at: $90.00
Special Price Starting at:
$135.00
ABT-492 is a new fluoroquinolone against 155 aerobic and 171 anaerobic pathogens. ...
Special Price Starting at: $135.00
Special Price Starting at:
$120.00
A-1331852 is a potent and selective BCL-XL inhibitor. BCL-XL is the major antiapoptotic survival protein and may be a novel therapeutic target in CML. ...
Special Price Starting at: $120.00
Special Price Starting at:
$108.00
ABT-199 is a so-called BH3-mimetic drug, which is designed to block the function of the protein Bcl 2. ...
Special Price Starting at: $108.00
Special Price Starting at:
$36.00
Linifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-β, KDR, and CSF-1R, respectively.
...
Special Price Starting at: $36.00
Special Price Starting at:
$90.00
BH3I-1 is a cell permeable BH3 mimetic that binds to Bcl-xL ...
Special Price Starting at: $90.00
Special Price Starting at:
$140.00
BM-1074 is a potent and efficacious Bcl-2/Bcl-xL inhibitor with Ki of <1 nM. ...
Special Price Starting at: $140.00
Special Price Starting at:
$40.00
ABT-888(Veliparib) is a potential anti-cancer drug acting as a PARP inhibitor. ...
Special Price Starting at: $40.00
Special Price Starting at:
$80.00
AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32μM, 0.48μM and 0.18μM. ...
Special Price Starting at: $80.00
Special Price Starting at:
$54.00
LCL161 is an orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, with potential antineoplast ...
Special Price Starting at: $54.00
Special Price Starting at:
$45.00
ABT-263 (Navitoclax) is a potent orally bioavailable SMI that is structurally related to ABT-737. ABT-263 disrupts Bcl-2 - Bcl-XL interactions with pro-apoptotic proteins . ...
Special Price Starting at: $45.00
Special Price Starting at:
$350.00
Bcl-2 Inhibitor contains a mixture of two tautomers. A potent, cell-permeable, Bcl-2 inhibitor competes with Bak BH3 peptide for binding to Bcl-2 and Bcl-XL in vitro (IC50 =10 uM and 7 uM, respectivel ...
Special Price Starting at: $350.00
Special Price Starting at:
$72.00
ABT-751 is an antimitotic agent, inhibits microtubule polymerization, binds to β-tubulin on the colchine site; blocks cell cycle at G2M phase and induces apoptosis. ...
Special Price Starting at: $72.00
Special Price Starting at:
$100.00
AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM; does not inhibit BIR3 domain and BID
...
Special Price Starting at: $100.00
Special Price Starting at:
$80.00
TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer mediated through a novel pathway involving inactivation of Notch-1 and Jagged-1. ...
Special Price Starting at: $80.00
Special Price Starting at:
$120.00
A-1155463 is a highly potent and selective BCL-XL inhibitor, A-1155463 shows picomolar binding affinity to BCL-XL (Ki ??0.01 nM), and >1000-fold weaker binding to BCL-2 (Ki = 80 nM) and related protei ...
Special Price Starting at: $120.00
Special Price Starting at:
$145.00
Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
...
Special Price Starting at: $145.00
Special Price Starting at:
$36.00
Pomalidomide is a derivative of thalidomide and acts as an immunomodulator. ...
Special Price Starting at: $36.00
Special Price Starting at:
$60.00
A-1210477 is a potent and selective MCL-1 inhibitor. A-1210477 induces the hallmarks of intrinsic apoptosis and demonstrates single agent killing of multiple myeloma and non-small cell lung cancer cel ...
Special Price Starting at: $60.00
Special Price Starting at:
$63.00
Gambogic acid is a natural product isolated from the Garcinia hanburyi tree. Gambogic Acid activates caspases with EC50 of 0.78-1.64 μM and competitively inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 a ...
Special Price Starting at: $63.00
Special Price Starting at:
$36.00
YM155 is a novel small molecule survivin suppressant with an IC50 of 0.54 nM for the inhibition of survivin promoter activity. ...
Special Price Starting at: $36.00
Special Price Starting at:
$120.00
Muristerone A is a phytoecdysteroid analog of ecdysone which induces genes in mammalian cells and causes apoptosis in cells transfected with wild-type Bax. ...
Special Price Starting at: $120.00
Special Price Starting at:
$58.50
MDM2 antagonist nutlin-3 is a potent inducer of apoptosis. ...
Special Price Starting at: $58.50
Keywords:buy Obatoclax mesylate (GX15-070) | Obatoclax mesylate (GX15-070) Supplier | purchase Obatoclax mesylate (GX15-070) | Obatoclax mesylate (GX15-070) cost | Obatoclax mesylate (GX15-070) manufacturer | order Obatoclax mesylate (GX15-070) | Obatoclax mesylate (GX15-070) distributor | buy 803712-79-0| 803712-79-0 Supplier | purchase 803712-79-0 | 803712-79-0 cost | 803712-79-0 manufacturer | order 803712-79-0 | 803712-79-0 distributor
We Using Safe Payments:
